NAFLD相关肝细胞癌:当前与新兴治疗的安全性和疗效
全球肥胖与2型糖尿病增加使NAFLD/NASH成为日益重要的HCC病因。NAFLD-HCC可达50%无肝硬化,年发病率较低,患者年龄较大且更多晚期诊断;局部治疗疗效可能不受病因影响,TKI可能同样有效,但免疫检查点抑制剂在NAFLD-HCC中可能疗效较差,现有指南未考虑病因。
要点
- NAFLD-HCC可达50%无肝硬化,年发病率较低,监测策略复杂。
- NAFLD-HCC患者年龄较大,更多在晚期诊断。
- 免疫检查点抑制剂在NAFLD-HCC中可能较病毒性HCC疗效差。
核心结论
- NAFLD/NASH是日益重要的HCC病因,现有指南未考虑病因,未来试验应评估病因对治疗安全性和疗效的影响。
研究设计与样本
- 本文为综述,聚焦NAFLD驱动HCC的当前与新兴治疗选择。
主要发现
- 与病毒驱动HCC不同,高达50%的NAFLD-HCC发生在无肝硬化患者中。
- NAFLD-HCC年发病率相对较低,患者平均年龄更大且更常晚期诊断。
- 局部区域治疗可能不受HCC病因影响,酪氨酸激酶抑制剂可能同样有效。
- 初步信号提示免疫检查点抑制剂在NAFLD-HCC中可能较病毒性HCC疗效差。
关键数值与推荐
- 当前国际HCC临床实践指南不考虑病因,因数据不足无法推荐病因特异性调整。
临床怎么用
- 临床应认识NAFLD-HCC可无肝硬化且常晚期诊断,现有指南管理未按病因区分。
局限性
- 病因对系统治疗疗效影响的数据不足,需未来临床试验评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In light of a global rise in obesity and type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) represent an increasingly important underlying aetiology of hepatocellular carcinoma (HCC). HCCs arising from lipotoxicity-mediated chronic inflammation are characterised by several unique features: in contrast to virally driven HCC, up to 50% of NAFLD-HCC occurs in patients without cirrhosis and annual HCC incidence is comparatively low, complicating current surveillance strategies. On average, patients are older and are more frequently diagnosed at an advanced stage. While locoregional treatments are probably equally effective regardless of HCC aetiology, the picture is less clear for systemic therapy. Tyrosine kinase inhibitors are probably equally effective, while there have been initial signals that immune checkpoint inhibitors may be less effective in NAFLD-HCC than in viral HCC. Current international clinical practice guidelines for HCC do not consider aetiology, as there are insufficient data to draw specific conclusions or to recommend aetiology-specific modifications to the current management of patients with HCC. However, in light of the growing relevance of NAFLD-HCC, future clinical trials should assess whether HCC aetiology - and NAFLD/NASH in particular - influence the safety and efficacy of a given treatment.
引用
- Foerster F, Gairing SJ, Müller L, et al. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol. 2021. PMID: 34555422. doi:10.1016/j.jhep.2021.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。